Bank of New York Mellon Corp Purchases 20,385 Shares of IQVIA Holdings Inc. $IQV

Bank of New York Mellon Corp lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,023,985 shares of the medical research company’s stock after buying an additional 20,385 shares during the quarter. Bank of New York Mellon Corp owned about 0.60% of IQVIA worth $194,496,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently made changes to their positions in IQV. Brighton Jones LLC increased its stake in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IQVIA during the second quarter worth about $514,000. Farther Finance Advisors LLC raised its holdings in shares of IQVIA by 34.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 398 shares of the medical research company’s stock worth $63,000 after acquiring an additional 101 shares during the last quarter. Finally, Truist Financial Corp lifted its position in IQVIA by 8.4% in the 2nd quarter. Truist Financial Corp now owns 159,707 shares of the medical research company’s stock valued at $25,168,000 after acquiring an additional 12,424 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 2.4%

Shares of NYSE IQV opened at $229.93 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The business has a 50-day moving average of $230.94 and a 200-day moving average of $208.19. The firm has a market capitalization of $39.16 billion, a price-to-earnings ratio of 31.54, a PEG ratio of 2.39 and a beta of 1.36. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the prior year, the firm earned $2.84 earnings per share. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently issued reports on IQV. Morgan Stanley upped their target price on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. TD Cowen upped their price objective on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. UBS Group lifted their target price on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. HSBC raised IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, Evercore ISI boosted their price objective on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.